NantKwest

89 articles about NantKwest

• NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients

  5/18/2020

  Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm Trial anticipated to initiate in Los Angeles area hospitals in Q2 Proprietary automated “GMP-in-a-Box”, an in-house manufacturing apparatus, enables rapidly scalable, off-the-shelf allogeneic mesenchymal stem cell product BM-Allo.MSC EL SEGUNDO, Calif.--

• NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer

  5/14/2020

  Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone

• NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference

  4/29/2020

  NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20 pm ET.

• 

  Clinical Catch-Up: April 13-17

  4/20/2020

  There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.

• NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter

  4/14/2020

  Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS) Vaccine Vector to Protect Against SARS-CoV-2 Infection: ImmunityBio’s Ad5: A second -generation adenovirus vaccine platform with four deletions enabling multiple homologous doses, even in patients with aden

• 

  WHO: More than 70 COVID-19 Vaccines are in Development, Three in Clinical Trials

  4/14/2020

  It’s likely that more companies and universities will add additional assets as time goes on.

• NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells

  3/19/2020

  Clinical trial for patients failing checkpoint therapy uses combination of first-in-class, cryopreserved, CD16 NK cells, ImmunityBio’s IL-15 superagonist and checkpoint inhibitor Avelumab EL SEGUNDO, Calif.--( BUSINESS WIRE )-- NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer and infectious diseases, today

• CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin

  1/29/2020

  CytRx Licensee ImmunityBio, Previously NantCell, Inc., Announced Complete Response in Metastatic Pancreatic Cancer with Its Human Natural Killer Cell Combination Immunotherapy Including Aldoxorubicin

• 

  Clinical Catch-Up: January 13-17

  1/20/2020

  There were plenty of clinical trial announcements this week. Here's a look.
• 

  Critics Underwhelmed by Patrick Soon-Shiong's 'Cancer Moonshot' Progress So Far

  1/15/2020

  In 2016, Soon-Shiong announced the Cancer Moonshot and set a 2020 deadline, claiming he would transform the war on cancer.

• NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS

  12/16/2019

  World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation

• NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers

  12/2/2019

  NantKwest, Inc. (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced promising safety data generated from the first six patients in its QUILT-3.064 trial.

• NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors

  11/27/2019

  This event will feature presentations from KOLs George Ansstas, MD, Washington University of Medicine in St. Louis, Chaitali Nangia, MD, Chan Soon-Shiong Institute for Medicine, and Clint Allen, MD, Johns Hopkins Kimmel Cancer Center, as well as Dr. Patrick Soon-Shiong, Chief Executive Officer and Chairman of NantKwest.

• NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors

  6/24/2019

  NantKwest Inc. (Nasdaq:NK), today announced that the company’s PD-L1 t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial in patients with locally advanced or metastatic solid cancers

• NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics

  6/4/2019

  Phase Ib/II Clinical Trial Data Reported at 2019 Annual Meeting of the American Society of Clinical Oncology Shows High Overall Objective Response Rate (ORR) of 58% and Complete Response Rate (CR) of 33% in Relapsed/Refractory Lymphoma Patients

• NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients

  6/4/2019

  5 out of 35 Durable Complete Responses Observed in Patients with Relapsed Third-Line Advanced Solid Tumors with Duration Ranging 4 to 24 Months

• NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference

  6/3/2019

  NantKwest, a leading clinical-stage, natural killer cell based therapeutics company, announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being held in New York City from June 4th-7th, 2019.

• NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients

  6/3/2019

  NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that the company’s t-haNK investigational new drug application (IND) has cleared FDA review

• NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate

  4/1/2019

  New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019

• NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy

  3/25/2019

  Completion of Phase 1 First-in-Human Trials of Cryopreserved, Off-The-Shelf haNK Cells Leads the Way to Pivotal Phase 2 Trials in Relapsed Merkel Cell Carcinoma